Global provider of drug development and delivery solutions, Patheon says it expects to invest approximately US$45 million at key sites across its global network to meet growing customer demand for expanded service capabilities. The company is investing in the following key areas:
Commercial & Development Spray Drying
The recently acquired site in Florence, South Carolina, will have commercial spray drying capabilities added, complementing the existing development capabilities available at the company’s low-solubility centre of excellence in Bend, Oregon.
The 15000 square feet (1393 m2) dedicated suite will contain two spray dryers delivering development and commercial scale spray-dried dispersion (SDD) services. The suite is expected to be online in 2019. Spray drying is applied to drug ingredients to create amorphous solid dispersions and is a key technology used to enhance the solubility of poorly soluble drugs.
At the Bend, Oregon site, the company plans to expand existing development SDD capabilities with a new cGMP analytical lab, manufacturing suite and additional development scale spray drying. Together, the expertise and capabilities at the Florence and Bend locations provide clients with solutions to solubility challenges.
Flexible manufacturing
Patheon has invested in a new commercial sterile product manufacturing facility in its Monza, Italy site. The facility will house three, 430 square feet (40 m2) lyophilisers with associated eight-headed integrated filling equipment for both lyo and liquid formulations for small and large molecules in a range of vial specifications. The equipment will have full CIP/SIP systems, auto loading for the lyophilisers contained in full RABs systems to ensure the highest level of sterility assurance.
A new commercial sterile product manufacturing facility will be housed at the Monza, Italy site
The company also plans to expand its sterile product Pharmaceutical Development Services (PDS) at the Monza facility. The sterile suite will contain two 75 square feet (7 m2) lyophilisers and associated sterile vial filling line and analytical laboratory.
This new facility will serve the company’s clients seeking to develop both small and large molecule injectable products (liquid and lyo formulations) and will be operational in mid-2019. All of Patheon’s PDS sterile suites are co-located within facilities with commercial scale capabilities to ease with the transition from clinical to commercialisation.
The company will expand its packaging and serialisation capabilities at its Greenville, NC site. The company has built a new filling and packaging suite and upgraded another of its packaging lines with new technology to improve efficiency and reduce change-over time.
The newly constructed 4800 square feet (446 m2) suite will come online this fall and features a filling and packaging line equipped with an Optel serialisation system. The system includes cameras, pharma proof stations, line master, and bottle and bundle tracker equipment.
All the investments are designed to improve efficiency and accelerate the delivery of clients products to market.
“As outsourcing of Pharma development and manufacturing services continues to grow, our customers will need even more advanced technologies and customised solutions to meet their business needs,” said Michel Lagarde, President of Patheon.
“With the increasing marketplace pressures, pharma companies are looking to build more reliable, flexible and cost-efficient supply chains. With our focus on people, process and capabilities, Patheon is uniquely positioned to partner with pharma companies to achieve their objectives — cost effectively while delivering the highest quality.”
